The receptor CDCP1 is emerging as a target for theranostics and ADCs for multiple cancers including ovarian cancer, PDAC and castration resistant prostate cancer including PSMA null disease 12-15, 26, 27. This evidence concerns the gene FOLH1 and cancer.